Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasophthalmology

Paeds Vivas · ophthalmology

Colour vision deficiency and inherited retinal disease: Viva

Branching clinical structured oral on colour vision deficiency and inherited retinal disease in children, covering the Ishihara test and the X-linked red-green defect, the retinitis pigmentosa and the Stargardt disease, the Leber congenital amaurosis and the RPE65 gene, the electroretinography and the molecular genetic testing, the choroideremia and the X-linked retinoschisis, the voretigene neparvovec gene therapy, and the distinction of the benign colour defect from the serious progressive dystrophy.

branching clinical structured oral5 min readVerification in progress

Target exams

RACP DWERACP DCEMRCPCH Clinical
On this page
Study tools

Target exams

RACP DWERACP DCEMRCPCH Clinical
Prompt
A six-year-old boy is referred because his teacher has noticed he confuses the red and the green of the classroom materials. The visual acuity is normal, the fields are full and the fundus are healthy, and the Ishihara test shows the red-green defect. The examiner asks how you frame the problem, how you perform and interpret the Ishihara test, what the inheritance means, and how your approach changes when the child instead presents with the progressive night blindness of the retinitis pigmentosa, and the nystagmus and the poor vision of the infant with the Leber congenital amaurosis treated by the voretigene neparvovec gene therapy.

This is a branching oral built to probe the reasoning that holds the colour vision test and the inheritance at the centre, the electroretinography and the molecular genetics of the inherited retinal disease, and to expose the candidate who has memorised the headline of the gene therapy without the safety-critical corners. The questions escalate from the framing to the Ishihara test, the inheritance, the retinitis pigmentosa and the Leber congenital amaurosis, with deliberate probes into the choroideremia and the gene therapy. [6]

Opening question: framing the problem

The examiner opens with the boy who confuses the red and the green and asks: how do you frame this problem, and what is your first step? [6]

A strong answer names the congenital red-green colour vision deficiency, confirms the finding with the formal Ishihara test, and states that the first step is the exclusion of the acquired cause and the reassurance. [6]

Model answer. This boy has the congenital red-green colour vision deficiency, the common X-linked recessive trait, and the first step is to confirm it with the formal Ishihara test, to exclude the acquired cause by confirming the normal acuity, the full fields and the healthy fundus, and to reassure the family that the condition is stable, inherited and benign. The normal acuity and the healthy fundus distinguish it from the acquired defect and the inherited retinal dystrophy. [6]

Probe one: the Ishihara test

The examiner presses: describe the Ishihara test, and tell me its limitation. [6]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]Hartong DT, Berson EL, Dryja TP Retinitis pigmentosa. Lancet, 2006.PMID 17113430
  2. [2]Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retin Eye Res, 2024.PMID 38278208
  3. [3]Russell S, Bennett J, Wellman JA, et al Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017.PMID 28712537
  4. [6]Birch J Worldwide prevalence of red-green color deficiency. J Opt Soc Am A Opt Image Sci Vis, 2012.PMID 22472762
  5. [8]Berger W, Kloeckener-Gruissem B, Neidhardt J The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res, 2010.PMID 20362068
  6. [9]Sheck LHN, Esposti SD, Mahroo OA, et al. Panel-based genetic testing for inherited retinal disease screening 176 genes. Mol Genet Genomic Med, 2021.PMID 33749171
  7. [11]Tan TE, Sun CZY, Poh SSJ, et al. One down but many more to go: the state of gene therapy for inherited retinal disease. Regen Med, 2025.PMID 41054259
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousWorking with interpreters and culturally responsive communication — branching vivaprofessional-practice-and-evidenceNextCongenital cataract and glaucoma — branching vivaophthalmology